In his session presented at Dermatology Week 2022, Joel Gelfand, MD, MSCE, discussed the current treatment landscape for psoriasis using recent data on IL-12, IL-23, and IL-17 inhibitors.
In his session presented at Dermatology Week 2022, Joel Gelfand, MD, MSCE, discussed the current treatment landscape for psoriasis using recent data on IL-12, IL-23, and IL-17 inhibitors.
Adult patients with atopic dermatitis (AD) are at increased risk for developing melanoma, squamous cell carcinoma, and basal cell carcinoma regardless of AD severity, according to a poster presented at the 2023 AAD Annual Meeting.
Adult patients with atopic dermatitis (AD) are at increased risk for developing melanoma, squamous cell carcinoma, and basal cell carcinoma regardless of AD severity, according to a poster presented at the 2023 AAD Annual Meeting.
Researchers aimed to evaluate cardiovascular risk in Slovak patients with psoriasis and investigate the relationship between cardiovascular risk and psoriasis features.
Researchers aimed to evaluate cardiovascular risk in Slovak patients with psoriasis and investigate the relationship between cardiovascular risk and psoriasis features.
Researchers aimed to evaluate serum levels of inflammatory cytokines, specifically tumor necrosis factor-alpha and IL-17, in patients with nail psoriasis.
Researchers aimed to evaluate serum levels of inflammatory cytokines, specifically tumor necrosis factor-alpha and IL-17, in patients with nail psoriasis.
